Multiple myeloma (MM) is a hematologic malignancy defined by the clonal proliferation of
transformed plasma cells. Despite tremendous advances in the treatment paradigm of MM, a …

Chimeric antigen receptor T cells (CAR-T cells) have emerged as a potentially
transformative new approach to treating hematological malignancies. Ide-cel, an autologous …

PURPOSE ABBV-383, a B-cell maturation antigen× CD3 T-cell engaging bispecific
antibody, has demonstrated promising results in an ongoing first-in-human phase I study …

Multiple myeloma (MM) remains an incurable hematologic malignancy, despite the
development of numerous innovative therapies during the past two decades …

The therapeutic landscape of multiple myeloma (MM) has benefited from an emergence of
novel therapies over the last decade. By inducing T-cell kill of target cancer cells, chimeric …

Despite advances in treatment for multiple myeloma, the majority of patients ultimately
develop relapsed disease marked by immune evasion and resistance to standard therapy …

Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapeutic approach
in the treatment of multiple myeloma, and the recent approval of the first two CAR T-cell …

Abstract αβ T cell receptor (TCRαβ) T cells modified to express chimeric antigen receptors
(CAR), are now available as authorized therapies for certain B-cell malignancies. However …

Advanced gene transfer technologies and profound immunological insights have enabled
substantial increases in the efficacy of anticancer adoptive cellular therapy (ACT). In recent …

Immunomodulatory imide drugs (IMiDs), proteasome inhibitors (PIs) and anti‐CD38
monoclonal antibodies (MoAbs) are the pillars of modern multiple myeloma (MM) therapy …